Shopping Cart is Empty..

$ 0

Europe Kidney Cancer Drugs Market by Product Type (Angiogenesis Inhibitors, Immunotherapies, Monoclonal Antibodies (mAbs), mTOR Inhibitors, and Generics), By Brand [Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), and Votrient (Pazopanib)] - Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals		Pages: NA	Formats*:
Oct 2017 \| 27 Views	Charts: NA	Tables: NA	Author(s): NA

Kidney cancer is a disease in which kidney cells become malignant and grow out of control, forming a tumor. The symptoms of renal cancer include blood in the urine, getting lumps or mass in sides or abdomen, weight loss, lethargy, and fever. The kidney cancer drug is normally given to patients who have reached stage four renal cell carcinoma.

Factors such as increasing incidences of kidney cancers due to reduced activity & sedentary lifestyle, growing geriatric population, and rise in cigarette smoking cases are the major factors that drive the market. However, high prices of branded drugs and side-effects associated with these drugs may hamper the growth of the kidney cancer drug market. Increase in R&D investments and introduction of novel molecules for drug delivery may boost the market opportunities in future.

The European kidney cancer drug market is segmented on the basis of product type, brand, and countries. Based on type, it is segmented into angiogenesis inhibitors, immunotherapies, monoclonal antibodies (mAbs), mTOR inhibitors, generics, and other products. On the basis of brand, the kidney cancer drug market is segmented into Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib), and others. Geographically the market has been analyzed across Germany, UK, France, Italy, Spain, and rest of Europe.

The major players in the kidney cancer drug market are F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Onyx Pharmaceuticals Inc., Bayer AG, Active Biotech AB, Novartis AG, Amgen, Genentech, Inc., Cipla Limited, and Pfizer Inc.

Key Benefits

The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate imminent investment pockets.
Extensive analysis of the market has been conducted by following key product positioning and monitoring the top competitors within the market framework.
It offers a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on prevailing market opportunities.
Key players have been profiled and their strategies thoroughly analyzed to understand the competitive outlook of the European market.
Comprehensive analysis of all countries in Europe has been provided that determines prevailing opportunities.

Europe Kidney Cancer Drugs Market Key Segment:

By Product Type

Angiogenesis Inhibitors
Immunotherapies
Monoclonal Antibodies (mAbs)
mTOR Inhibitors
Generics
Other Products

By Brand

Afinitor (Everolimus)
Avastin (Bevacizumab)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Sutent (Sunitinib)
Torisel (Temsirolimus)
Votrient (Pazopanib)
Others

By Country

Germany
UK
France
Italy
Spain
Rest of Europe

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

License Type

Data Pack

Single User PDF

Five User Online/PDF

Enterprise Online/PDF

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

One Print only

Up to Five Copies

Unlimited within company / enterprise

Delivery Formats

ADDED BENIFITS

20% Free customization (Pre-sale)

16 Analyst hour support (Post Sale)

40 Analyst hour support (Post Sale)

160 hours of mini-consult

Free quarterly industry update

Free report on update (within 180 days)

MULTIPLE PURCHASE

Complimentary report with 2 reports

Complimentary report with 3 reports

Subscription Model

Have questions ?
Speak with analyst

Did you miss anything?
To add more

* Taxes/Fees, If applicable, will be
added at the checkout. All prices in USD.

Need More Information

+1-503-894-6022

help@alliedmarketresearch.com

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to eliminate redundant information to provide valued information and save time of the reader

Get fresh content delivered

Get insights on topics that matter to your business. Stay updated on the areas that interest you.

Report Title: Europe Kidney Cancer Drugs Market by Product Type (Angiogenesis Inhibitors, Immunotherapies, Monoclonal Antibodies (mAbs), mTOR Inhibitors, and Generics), By Brand [Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), and Votrient (Pazopanib)] - Opportunity Analysis and Industry Forecast, 2017-2023

Select Chapters

Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7

Full Name: *:

Company Name: *:

Job Role: *:

Email: *:

Country: *:

Contact Number: *:

How can we help? *:

Security Code: *:

STAY WITH US

WE ACCEPT

* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Chapter: 1 INTRODUCTION 1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models
Chapter: 2 EXECUTIVE SUMMARY 2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW 3.1. MARKET DEFINITION AND SCOPE 3.2. KEY FINDINGS 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. MARKET SHARE ANALYSIS, 2016 3.4. PORTER’S FIVE FORCES ANALYSIS 3.4.1. MARKET DYNAMICS 3.4.2. Drivers 3.4.3. Restraints 3.4.4. Opportunities
Chapter: 4 EUROPE KIDNEY CANCER DRUGS MARKET, BY PRODUCT TYPE 4.1. OVERVIEW 4.1.1. Market size and forecast 4.2. ANGIOGENESIS INHIBITORS 4.2.1. Key market trends 4.2.2. Growth factors and opportunities 4.2.3. Market size and forecast 4.3. IMMUNOTHERAPIES 4.3.1. Key market trends 4.3.2. Growth factors and opportunities 4.3.3. Market size and forecast 4.4. MONOCLONAL ANTIBODIES (MABS) 4.4.1. Key market trends 4.4.2. Growth factors and opportunities 4.4.3. Market size and forecast 4.5. MTOR INHIBITORS 4.5.1. Key market trends 4.5.2. Growth factors and opportunities 4.5.3. Market size and forecast 4.6. GENERICS 4.6.1. Key market trends 4.6.2. Growth factors and opportunities 4.6.3. Market size and forecast 4.7. OTHER PRODUCTS 4.7.1. Key market trends 4.7.2. Growth factors and opportunities 4.7.3. Market size and forecast
Chapter: 5 EUROPE KIDNEY CANCER DRUGS MARKET, BY BRAND 5.1. OVERVIEW 5.1.1. Market size and forecast 5.2. AFINITOR (EVEROLIMUS) 5.2.1. Market size and forecast 5.3. AVASTIN (BEVACIZUMAB) 5.3.1. Market size and forecast 5.4. INLYTA (AXITINIB) 5.4.1. Market size and forecast 5.5. NEXAVAR (SORAFENIB) 5.5.1. Market size and forecast 5.6. PROLEUKIN (ALDESLEUKIN) 5.6.1. Market size and forecast 5.7. SUTENT (SUNITINIB) 5.7.1. Market size and forecast 5.8. TORISEL (TEMSIROLIMUS) 5.8.1. Market size and forecast 5.9. VOTRIENT (PAZOPANIB) 5.9.1. Market size and forecast 5.10. OTHERS 5.10.1. Market size and forecast
Chapter: 6 EUROPE KIDNEY CANCER DRUGS MARKET, BY COUNTRY 6.1. OVERVIEW 6.2. KEY MARKET TRENDS 6.3. KEY GROWTH FACTORS AND OPPORTUNITIES 6.4. MARKET SIZE AND FORECAST 6.4.1. Germany market size and forecast 6.4.2. UK market size and forecast 6.4.3. France market size and forecast 6.4.4. Italy market size and forecast 6.4.5. Spain market size and forecast 6.4.6. Rest of Europe market size and forecast
Chapter: 7 COMPANY PROFILES 7.1. F. HOFFMANN-LA ROCHE AG 7.1.1. Operating business segments 7.1.2. Business performance 7.1.3. Key strategic moves and developments 7.2. GLAXOSMITHKLINE PLC 7.2.1. Operating business segments 7.2.2. Business performance 7.2.3. Key strategic moves and developments 7.3. ONYX PHARMACEUTICALS INC. 7.3.1. Operating business segments 7.3.2. Business performance 7.3.3. Key strategic moves and developments 7.4. BAYER AG 7.4.1. Operating business segments 7.4.2. Business performance 7.4.3. Key strategic moves and developments 7.5. ACTIVE BIOTECH AB 7.5.1. Operating business segments 7.5.2. Business performance 7.5.3. Key strategic moves and developments 7.6. NOVARTIS AG 7.6.1. Operating business segments 7.6.2. Business performance 7.6.3. Key strategic moves and developments 7.7. AMGEN 7.7.1. Operating business segments 7.7.2. Business performance 7.7.3. Key strategic moves and developments 7.8. GENENTECH, INC. 7.8.1. Operating business segments 7.8.2. Business performance 7.8.3. Key strategic moves and developments 7.9. CIPLA LIMITED 7.9.1. Operating business segments 7.9.2. Business performance 7.9.3. Key strategic moves and developments 7.10. PFIZER INC. 7.10.1. Operating business segments 7.10.2. Business performance 7.10.3. Key strategic moves and developments

Purchase Options